iShares STOXX Europe 600 UCITS ETF (DE) EUR (Dist) is a equity ETF from iShares tracking the STOXX Europe 600 index through physical replication. Domiciled in Germany and launched in 2004, the fund manages about 9.5 bn € and charges a TER of 0.20% — 20 € per year on a €10,000 investment. Income is paid out to investors periodically (distributing).
iShares STOXX Europe 600 UCITS ETF (DE) EUR (Dist) competes with 3 other products on the same index (STOXX Europe 600): it ranks 2nd by fund size and 3rd by ongoing cost, with a TER of 0.20% against a group median of 0.20%. It has been listed since 2004, 22 years of track record — the oldest in its comparison group.
On a €10,000 investment the TER costs 20 € a year. The cheapest of the group is Amundi Stoxx Europe 600 (Acc) at 0.07%, or 7 € on the same amount: a difference of 13 € every year, roughly 130 € over ten years before compounding.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 20.0% of the portfolio.
Income is distributed periodically: it produces cash flow, but reinvesting it is up to you if the goal is capital growth. The fund is denominated in EUR. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Germany, which determines the tax treatment of income received by the fund and the supervisory authority.
| ASML Holding N.V. | 5.0% |
| HSBC Holdings PLC | 2.1% |
| Novartis AG | 2.0% |
| Roche Holding AG | 1.9% |
| AstraZeneca PLC | 1.9% |
| Nestle S.A. | 1.7% |
| Siemens Aktiengesellschaft | 1.5% |
| Shell plc | 1.4% |
| Banco Santander S.A. | 1.3% |
| Schneider Electric S.E. | 1.2% |
| Borsa Italiana | EXSA | EUR |
| XETRA | EXSA | EUR |
| Francoforte | EXSA | EUR |
| SIX Swiss Exchange | SXPIEX | EUR |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.